Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514Actinium PharmaceuticalsPhase 2, Phase 3Not yet recruiting2029-02Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.